| Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity M Kågedahl, PW Swaan, CT Redemann, M Tang, CS Craik, FC Szoka, ... Pharmaceutical research 14, 176-180, 1997 | 64 | 1997 |
| A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066—estimating occupancy in the absence of a reference region M Kågedal, Z Cselényi, S Nyberg, P Raboisson, L Ståhle, P Stenkrona, ... Neuroimage 82, 160-169, 2013 | 49 | 2013 |
| Modelling a spontaneously reported side effect by use of a Markov mixed-effects model PH Zingmark, M Kågedal, MO Karlsson Journal of pharmacokinetics and pharmacodynamics 32, 261-281, 2005 | 47 | 2005 |
| Blood–brain barrier penetration of zolmitriptan—modelling of positron emission tomography data M Bergström, R Yates, A Wall, M Kågedal, S Syvänen, B Långström Journal of pharmacokinetics and pharmacodynamics 33, 75-91, 2006 | 41 | 2006 |
| Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR S Nyberg, A Jucaite, A Takano, M Kågedal, Z Cselényi, C Halldin, L Farde International Journal of Neuropsychopharmacology 16 (10), 2235-2244, 2013 | 36 | 2013 |
| Time‐to‐event analysis of polatuzumab vedotin‐induced peripheral neuropathy to assist in the comparison of clinical dosing regimens D Lu, WR Gillespie, S Girish, P Agarwal, C Li, J Hirata, YW Chu, ... CPT: Pharmacometrics & Systems Pharmacology 6 (6), 401-408, 2017 | 34 | 2017 |
| Development of a subcutaneous fixed‐dose combination of pertuzumab and trastuzumab: results from the phase Ib dose‐finding study WP Kirschbrown, C Wynne, M Kågedal, R Wada, H Li, B Wang, I Nijem, ... The Journal of Clinical Pharmacology 59 (5), 702-716, 2019 | 33 | 2019 |
| Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers M Kågedal, Z Cselényi, S Nyberg, S Jönsson, P Raboisson, P Stenkrona, ... Neuroimage 61 (4), 849-856, 2012 | 30 | 2012 |
| Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C … K Varnäs, S Nyberg, P Karlsson, ME Pierson, M Kågedal, Z Cselényi, ... Psychopharmacology 213, 533-545, 2011 | 30 | 2011 |
| Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study A Wall, M Kågedal, M Bergström, E Jacobsson, D Nilsson, G Antoni, ... Drugs in R & D 6, 139-147, 2005 | 29 | 2005 |
| Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug … MZ Liao, D Lu, M Kågedal, D Miles, D Samineni, SN Liu, C Li Clinical Pharmacology & Therapeutics 110 (5), 1216-1230, 2021 | 28 | 2021 |
| Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology S Kawakatsu, R Bruno, M Kågedal, C Li, S Girish, A Joshi, B Wu British Journal of Clinical Pharmacology 87 (6), 2493-2501, 2021 | 25 | 2021 |
| True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers M Kågedal, PH Zingmark, C Hedlund, R Yates American Journal of Drug Delivery 3, 133-140, 2005 | 21* | 2005 |
| PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects S Nyberg, A Takano, A Jucaite, P Karlsson, D McCarthy, M Kagedal, ... European Neuropsychopharmacology 18, S270-S270, 2008 | 20 | 2008 |
| Evaluation of the effects of a metabotropic glutamate receptor 5‐antagonist on electrically induced pain and central sensitization in healthy human volunteers J Kalliomäki, K Huizar, M Kågedal, B Hägglöf, M Schmelz European Journal of Pain 17 (10), 1465-1471, 2013 | 15 | 2013 |
| A study of organic acid transporter-mediated pharmacokinetic interaction between NXY-059 and cefuroxime. M Kagedal, D Nilsson, G Huledal, I Reinholdsson, YF Cheng, N Asenblad, ... Journal of clinical pharmacology 47 (8), 1043-1049, 2007 | 15 | 2007 |
| Intrinsic and extrinsic pharmacokinetic variability of small molecule targeted cancer therapy E Reyner, B Lum, J Jing, M Kagedal, JA Ware, LJ Dickmann Clinical and Translational Science 13 (2), 410-418, 2020 | 13 | 2020 |
| Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC) SC Chen, M Kagedal, Y Gao, B Wang, ML Harle-Yge, S Girish, J Jin, C Li Cancer Chemotherapy and Pharmacology 80, 1147-1159, 2017 | 13 | 2017 |
| Early phase drug development for treatment of chronic pain—Options for clinical trial and program design J Kalliomäki, F Miller, M Kågedal, R Karlsten Contemporary clinical trials 33 (4), 689-699, 2012 | 12 | 2012 |
| Pharmacokinetics of the port delivery system with ranibizumab in the ladder phase 2 trial for neovascular age-related macular degeneration CC Wykoff, PA Campochiaro, DJ Pieramici, AM Khanani, S Gune, M Maia, ... Ophthalmology and Therapy 11 (5), 1705-1717, 2022 | 11 | 2022 |
Andrew C. HookerProfessor of Pharmacometrics, Uppsala UniversityVerified email at farmaci.uu.se
